Diabetes & metabolism最新文献

{"title":"Associations of dietary magnesium intake with the risk of atherosclerotic cardiovascular disease and mortality in individuals with and without type 2 diabetes: A prospective study in the UK Biobank","authors":"Ruyu Huang ,&nbsp;Xinxin Kong ,&nbsp;Rui Geng ,&nbsp;Jingwei Wu ,&nbsp;Jiong Li ,&nbsp;Yong Gu ,&nbsp;Yaqian Wu ,&nbsp;Dongfang You ,&nbsp;Yang Zhao ,&nbsp;Senmiao Ni ,&nbsp;Zihang Zhong ,&nbsp;Jianling Bai","doi":"10.1016/j.diabet.2024.101554","DOIUrl":"10.1016/j.diabet.2024.101554","url":null,"abstract":"<div><h3>Background</h3><p>The association between dietary magnesium (Mg) intake and the risk of atherosclerotic cardiovascular disease (ASCVD) remains uncertain. We aimed to examine the associations of dietary Mg intake with the risk of ASCVD events and mortality in individuals with and without type 2 diabetes.</p></div><div><h3>Methods</h3><p>A total of 149,929 participants (4603 with type 2 diabetes) from the UK Biobank were included in the analyses. The hazard ratios (HRs) and 95 % confidence intervals (CIs) were estimated using Cox proportional hazard models. Furthermore, interactions of dietary Mg intake with type 2 diabetes status were examined on multiplicative and additive scales.</p></div><div><h3>Results</h3><p>During a median follow-up of 12.0 and 12.1 years, 7811 incident ASCVD events and 5000 deaths (including 599 ASCVD deaths) were documented, respectively. There were significantly negative associations between sufficient dietary Mg intake (equal to or greater than the recommended daily intake) and the risk of ASCVD incidence (HR 0.63 [95 % CI 0.49;0.82]), ASCVD mortality (0.45 [0.24;0.87]), and all-cause mortality (0.71 [0.52;0.97]) in participants with type 2 diabetes, whereas no significant association was observed in participants without type 2 diabetes (1.01 [0.94;1.09] for ASCVD incidence; 1.25 [0.93;1.66] for ASCVD mortality; 0.97 [0.88;1.07] for all-cause mortality). Multiplicative and additive interactions of dietary Mg intake with type 2 diabetes status were both observed.</p></div><div><h3>Conclusion</h3><p>Sufficient dietary Mg intake was significantly associated with lower risks of ASCVD events and mortality in individuals with type 2 diabetes but not in those without type 2 diabetes. Our findings provide insight into the importance of dietary Mg intake for reducing modifiable cardiovascular burden in individuals with type 2 diabetes, which may inform future personalized dietary guidelines.</p></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"50 5","pages":"Article 101554"},"PeriodicalIF":4.6,"publicationDate":"2024-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141478281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is plasma 16:0 ceramide a marker of cardiovascular risk?","authors":"","doi":"10.1016/j.diabet.2024.101553","DOIUrl":"10.1016/j.diabet.2024.101553","url":null,"abstract":"","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"50 6","pages":"Article 101553"},"PeriodicalIF":4.6,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141474394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Averaged glycaemic variability or by average: More than a simple question of wording","authors":"Louis Monnier ,&nbsp;Claude Colette ,&nbsp;Fabrice Bonnet","doi":"10.1016/j.diabet.2024.101550","DOIUrl":"10.1016/j.diabet.2024.101550","url":null,"abstract":"","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"50 5","pages":"Article 101550"},"PeriodicalIF":4.6,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141474392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cutaneous hypersensitivity reaction to dulaglutide: A case report of an allergic reaction","authors":"C. Samhani ,&nbsp;B. Guerci ,&nbsp;C. Larose","doi":"10.1016/j.diabet.2024.101552","DOIUrl":"10.1016/j.diabet.2024.101552","url":null,"abstract":"<div><p>GLP-1 (glucagon-like peptide-1) receptor agonists are a class of anti-diabetic agents that act by inducing insulin secretion and inhibiting glucagon release in a glucose-dependent manner. They are particularly promising because of their long duration of action, reduced risk of hypoglycaemia and the added benefit of weight loss. Trulicity ® dulaglutide is a GLP-1 receptor agonist approved for type II diabetes and chronic weight management in obese adults.</p><p>A few rare cases of hypersensitivity reactions have been reported in patients taking the GLP-1 receptor agonists dulaglutide and liraglutide. Here we present a new case of cutaneous hypersensitivity reactions in a man taking dulaglutide for type II diabetes. A 52-year-old man who had been taking dulaglutide for 5 weeks developed a rash on the abdomen when the dose was increased for 3 months. The patient experienced resolution of symptoms within days of stopping dulaglutide.</p></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"50 5","pages":"Article 101552"},"PeriodicalIF":4.6,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141474393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of multiple sclerosis with incident diabetes: A nationwide cohort study","authors":"Jeppe Ravn Jacobsen ,&nbsp;Søren L. Kristensen ,&nbsp;Emil L. Fosbøl ,&nbsp;Lars Køber ,&nbsp;Lucas Malta Westergaard ,&nbsp;Frederik Persson ,&nbsp;Peter Rossing ,&nbsp;Rasmus Rørth","doi":"10.1016/j.diabet.2024.101551","DOIUrl":"10.1016/j.diabet.2024.101551","url":null,"abstract":"<div><h3>Aim</h3><p>Diabetes mellitus (DM) and multiple sclerosis (MS) are two common diseases known to worsen the trajectory of each other, yet it is unknown whether MS is associated with incident DM.</p></div><div><h3>Methods</h3><p>Using Danish nationwide registries, we identified all patients aged 18–99 with a first-time primary or secondary discharge diagnosis with MS between 2000 and 2018, with no known DM. These patients were matched with control subjects from the background population in a 1:5 ratio based on age and sex, to assess their risk of DM.</p></div><div><h3>Results</h3><p>A total of 13,376 patients with MS and 66,880 matched control subjects were included (33 % men; median age, 42 years [25th–75th percentile, 33–51]). During a median follow-up of 8.3 years (25th–75th percentile, 4.0–13.3), 467 (3.5 %) patients with MS and 2397 (3.6 %) control subjects were diagnosed with DM. The cumulative incidence of DM was similar among patients with MS and control subjects (95 % confidence interval [CI] 6.5 % [5.7–7.2 %] vs. 7.3 % [95 % CI 6.9–7.9 %], respectively), and adjusted analysis yielded a hazard ratio (HR) of 0.98 [95 % CI 0.89–1.09]). The overall risk of incident type 1 diabetes was low and yielded a HR of 1.60 [95 % CI 0.98–1.40] in patients with MS compared with control subject (<em>P</em> = 0.07).</p></div><div><h3>Conclusion</h3><p>This study demonstrated that patients with MS had a similar risk of incident DM as compared to age- and sex matched controls from the background population.</p></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"50 5","pages":"Article 101551"},"PeriodicalIF":4.6,"publicationDate":"2024-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141447933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Type B insulin resistance syndrome: A case report","authors":"Mathilde Sollier ,&nbsp;Corinne Vigouroux ,&nbsp;Katie Duckett ,&nbsp;Martine Auclair ,&nbsp;Virginie Lamand ,&nbsp;Sika Nassouri ,&nbsp;Cyril Garcia ,&nbsp;Lyse Bordier ,&nbsp;Weniko Caré","doi":"10.1016/j.diabet.2024.101549","DOIUrl":"10.1016/j.diabet.2024.101549","url":null,"abstract":"","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"50 5","pages":"Article 101549"},"PeriodicalIF":4.6,"publicationDate":"2024-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141447934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of podocyte ultrastructural changes with proteinuria and pathological classification in type 2 diabetic nephropathy","authors":"Yue Zhou ,&nbsp;Shuang Hou ,&nbsp;Xiao-yan Huang ,&nbsp;Dong-yuan Chang ,&nbsp;Hui Wang ,&nbsp;Lin Nie ,&nbsp;Zu-ying Xiong ,&nbsp;Min Chen ,&nbsp;Ming-hui Zhao ,&nbsp;Su-xia Wang","doi":"10.1016/j.diabet.2024.101547","DOIUrl":"10.1016/j.diabet.2024.101547","url":null,"abstract":"<div><h3>Aims</h3><p>Podocyte injury plays an essential role in the progression of diabetic nephropathy (DN). The associations between the ultrastructural changes of podocyte with proteinuria and the pathological classification of DN proposed by Renal Pathology Society (RPS) have not been clarified in patients with type 2 diabetic nephropathy (T2DN).</p></div><div><h3>Methods</h3><p>We collected 110 patients with kidney biopsy-confirmed T2DN at Peking University First Hospital from 2017 to 2022. The morphometric analysis on the podocyte foot process width (FPW) and podocyte detachment (PD) as markers of podocyte injury was performed, and the correlations between the ultrastructural changes of podocytes with severity of proteinuria and the RPS pathological classification of DN were analyzed.</p></div><div><h3>Results</h3><p>Mean FPW was significantly broader in the group of T2DN patients with nephrotic proteinuria (565.1 nm) than those with microalbuminuria (437.4 nm) or overt proteinuria (494.6 nm). The cut-off value of FPW (&gt; 506 nm) could differentiate nephrotic proteinuria from non-nephrotic proteinuria with a sensitivity of 75.3% and a specificity of 75.8%. Percentage of PD was significantly higher in group of nephrotic proteinuria (3.2%) than that in microalbuminuria (0%) or overt proteinuria (0.2%). FPW and PD significantly correlated with proteinuria in T2DN (<em>r</em> = 0.473, <em>p &lt; 0.001</em> and <em>r</em> = 0.656, <em>P &lt; 0.001</em>). FPW and PD correlated with RPS pathological classification of T2DN (<em>r</em> = 0.179, <em>P = 0.014</em> and <em>r</em> = 0.250, <em>P = 0.001</em>). FPW value was increased significantly with more severe DN classification (<em>P for trend =0.007</em>). The percentage of PD tended to increase with more severe DN classification (<em>P for trend = 0.017</em>).</p></div><div><h3>Conclusions</h3><p>Podocyte injury, characterized by FPW broadening and PD, was associated with the severity of proteinuria and the pathological classification of DN.</p></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"50 4","pages":"Article 101547"},"PeriodicalIF":7.2,"publicationDate":"2024-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141297779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Menopausal hormone therapy decreases the likelihood of diabetes development in peri‑menopausal individuals with prediabetes","authors":"Yu-Hsiang Shih ,&nbsp;Chiao-Yu Yang ,&nbsp;Shao-Jing Wang ,&nbsp;Chia-Chi Lung","doi":"10.1016/j.diabet.2024.101546","DOIUrl":"https://doi.org/10.1016/j.diabet.2024.101546","url":null,"abstract":"<div><h3>Background</h3><p>The influence of menopausal hormone therapy (MHT) on the probability of developing diabetes mellitus in individuals with prediabetes remains uncertain.</p></div><div><h3>Methods</h3><p>This retrospective cohort study, utilizing the TriNetX U.S. Collaborative Network, investigated cohorts, implemented propensity score matching, and analyzed outcomes associated with diabetes mellitus. The study focused on individuals aged 46–60 with prediabetes prior to menopause, categorizing them into MHT and non-MHT groups. Further stratified analyses, including variables such as age and race, were conducted to thoroughly examine potential variations in outcomes.</p></div><div><h3>Results</h3><p>The study involved 6566 individuals (MHT and non-MHT), with propensity score matching ensuring balanced cohorts. Over a 20-year follow-up, the MHT group demonstrated a lower incidence of diabetes mellitus compared to the non- MHT group, with a Hazard Ratio of 0.693 (95 % CI: 0.577, 0.832). Stratified analyses revealed age-specific nuances, with significant protective effects in individuals aged 46–50 and 55–60. Additionally, ethnicity played a role, with MHT demonstrating significant benefits in White individuals but not in the Black or Asian populations. BMI analysis indicated a significant risk reduction with MHT in individuals with BMI less than or equal to 24.9 and 25–29.9 kg/m ², but not in those with BMI greater than or equal to 30 kg/m ².</p></div><div><h3>Conclusion</h3><p>In our study, we demonstrate a sustained 20-year decrease in the risk of diabetes among premenopausal individuals with prediabetes who undergo menopausal hormone therapy.</p></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"50 4","pages":"Article 101546"},"PeriodicalIF":7.2,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1262363624000387/pdfft?md5=1148948294de47682eb3f31b27a7e665&pid=1-s2.0-S1262363624000387-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141250978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Closed-loop insulin delivery systems in patients with pancreatitis or pancreatectomy-induced diabetes: A case series","authors":"Menaouar Touimer ,&nbsp;Hana Charfi ,&nbsp;Antonio Sa Cunha ,&nbsp;Alfred Penfornis ,&nbsp;Coralie Amadou","doi":"10.1016/j.diabet.2024.101544","DOIUrl":"https://doi.org/10.1016/j.diabet.2024.101544","url":null,"abstract":"<div><p>Pancreatic diabetes is associated with glycemic variability, poor metabolic control, and reduced quality of life. Though hybrid closed-loop (HCL) insulin delivery systems were not originally developed for these types of diabetes, they could address the therapeutic challenge. We aimed to evaluate long-term metabolic control in ten adult patients (mean ± SD age: 59 ± 12) treated with HCL insulin delivery systems for pancreatitis or pancreatectomy-induced diabetes. After a median of 346 days (range 64 - 631) with HCL insulin delivery, continuous glucose monitoring showed 59±19 % time-in-range [70–180 mg/dl] (versus 49±24 % before HCL insulin delivery, <em>P</em> = 0. 049) and 0.8 ± 1.0 % time-below-range [&lt; 70 mg/dl] (versus 2.2 ± 2.6 %, <em>P</em> = 0.142), with the coefficient of glucose variability at 35.4 ± 7.6 (versus 37.8 ± 7.1, <em>P</em> = 0.047). Hb_A1c decreased from 8.5 ± 1.7 % to 7.7 ± 1.3 % [69±18 to 60±14 mmol/mol] (<em>P</em> = 0.076). No patient experienced an acute adverse metabolic event.</p></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"50 4","pages":"Article 101544"},"PeriodicalIF":7.2,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141090943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risks of carpal tunnel syndrome and carpal tunnel release surgery in users of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A target trial emulation study","authors":"Yu-Chi Su ,&nbsp;Pei-Chun Hsieh ,&nbsp;Edward Chia-Cheng Lai ,&nbsp;Yun-Cian Lin ,&nbsp;Yu-Ching Lin","doi":"10.1016/j.diabet.2024.101545","DOIUrl":"10.1016/j.diabet.2024.101545","url":null,"abstract":"<div><h3>Aim</h3><p>Preclinical studies have shown that sodium-glucose cotransporter 2 inhibitors (SGLT2is) have a neuroprotective effect. This study compared the risks of carpal tunnel syndrome and carpal tunnel release surgery between new users of SGLT2is and new users of glucagon-like peptide-1 receptor agonists (GLP-1RAs).</p></div><div><h3>Methods</h3><p>A retrospective new-user active comparator cohort study with a target trial design was conducted by using the TriNetX platform. Patients with type 2 diabetes mellitus prescribed SGLT2is or GLP-1RAs were identified. Covariates were balanced using propensity score matching to form 2 homogenous treatment groups. Outcomes were the risk of carpal tunnel syndrome and the risk of carpal tunnel release surgery. Hazard ratios (HRs) with 95 % confidence intervals (CIs) were calculated using the TriNetX platform.</p></div><div><h3>Results</h3><p>The crude cohort included 86,188 and 100,244 patients in the SGLT2is group and GLP-1RAs group, respectively. After matching, each group included 65,464 patients. The SGLT2is group had an average age of 59.6 years, and 46 % were women. The GLP-1RAs group had an average age of 59.5 years, and 45.9 % were women. The incidences of carpal tunnel syndrome (HR: 0.928; 95 % CI: 0.869 to 0.991) and carpal tunnel release surgery (HR: 0.840; 95 % CI: 0.726 to 0.971) were significantly lower in the SGLT2is group than in the GLP-1RAs group.</p></div><div><h3>Conclusion</h3><p>In patients with type 2 diabetes mellitus, SGLT2is seem to decrease the risk of carpal tunnel syndrome and the need for carpal tunnel release surgery. Prospective studies are required to confirm our results.</p></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"50 4","pages":"Article 101545"},"PeriodicalIF":7.2,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141082321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}